US › Healthcare

Can Fite Biopharma Ltd ADR (CANF)

US · Healthcare · Biotechnology

$1.76-4.86%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

$101,000

Revenue YoY

0.0%

Net profit

$-2.3M

EPS

$0.00

EPS estimate

$-2.40

Net margin

-2,277.7%

EPS came in at 0.00 against a street estimate of -2.40 — a beat of 100.0%.

Key statistics

Market cap

$5.9M

Forward P/E

3.0

P/B

0.95

Book value

$2.27

EPS (TTM)

$-13.23

52-week high

$11.02

52-week low

$1.90

50-day MA

$2.70

200-day MA

$3.37

Beta

-0.02

Analyst view

Analysts rate Can Fite Biopharma Ltd ADR a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $8.00.

Shareholding

Institutions

1.66%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Can Fite Biopharma Ltd ADR — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-18.